Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab + Tisotumab vedotin-tftv |
Indication/Tumor Type | cervical cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | cervical cancer | sensitive | Pembrolizumab + Tisotumab vedotin-tftv | Guideline | Actionable | Keytruda (pembrolizumab) combined with Tivdak (tisotumab vedotin-tftv) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic cervical cancer expressing CD274 (PD-L1, CPS>/=1) (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |